NKMAX Accelerates Full-Scale Commercialization of Japanese NK Cell Therapy
NKMAX has begun preparations for the commercialization of its NK cell therapy in Japan.
NKMAX announced on the 13th that PMDA (Pharmaceuticals and Medical Devices Agency), under Japan's Ministry of Health, Labour and Welfare, has completed an inspection of its NK cell therapy (SNK) GMP (Good Manufacturing Practice) facility.
Unlike in Korea, in Japan, regenerative medical treatments such as NK cell therapy can be administered based on a physician's judgment. In fact, once approved by the Regenerative Medicine Council in Japan, NK cell therapy can be administered for therapeutic purposes, enabling immediate revenue generation.
Following PMDA's approval of the GMP facility, NKMAX plans to finalize the commercialization process of SNK soon in collaboration with Japanese medical institutions and healthcare professionals. It is reported that frontline medical institutions are recruiting a large number of patients who are awaiting SNK administration.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
An NKMAX representative stated, “Having successfully completed the inspection, the commercialization of SNK in Japan is imminent,” adding, “We plan to continue the commercialization of SNK starting with Japan.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
